Business, energy, technology, markets and global industry news from Business News Today

IPH4502

PharmaDeviceNews IPH4502
Innate Pharma’s IPH4502 Phase 1 dose-escalation milestone advances its Nectin-4 exatecan ADC toward a 76-patient year-end readout in advanced solid tumors. Representative image.
Pharma & Biotech

Why Innate Pharma’s 76-patient IPH4502 milestone is only half the Nectin-4 story

Innate Pharma completed IPH4502 dose-escalation enrollment, putting safety, response durability and dose selection at the center of a year-end readout.

Read More
Representative image of a biotech conference setting as Innate Pharma heads to the Kempen Life Sciences Conference, where investors are expected to assess the outlook for IPH4502, lacutamab, and monalizumab within the company’s immuno-oncology pipeline.
Pharma & Biotech

What Innate Pharma’s Kempen conference participation reveals about its 2026 biotech strategy

Innate Pharma heads to Kempen as investors assess its oncology pipeline, partnering outlook, and next catalysts. Read the full analysis.

Read More